Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Zelda Therapeutics — Investor Presentation (February 2017)
9 slides from Zelira Therapeutics's investor presentation, February 2017
Slide 1: Bringing Together Leading Medicinal Cannabis Researchers
TI . . PE | r LY | l C >) BRINGING TOGETHER LEADING MEDICINAL CANNABIS RESEARCHERS Aunt Zelda's Top 25 Stocks Tamisium Extractors, Inc. ———>_ INSIDE: Cl Magazines Top 25 Stock Picks @
Slide 2: Zelda Therapeutics Ltd: About
ZELDA THERAPEUTICS LTD About with which medical cannabis is assisting. The prestigious US National Academy of Sciences, earlier this year, released the biggest independent review based on the level of research currently undertaken on the health Zelda Therapeutics Limited (“Zelda”) is an Australian o
Slide 3: Corporate Structure and Recent Achievements
Corporate Structure Recent Achievements Over the last 12 months the company has: Publicly listed on the Australian Market Capitalization Stock Exchange (ASX) in Nov 2016 Established a Medical Advisory Board with globally recognised leaders in their field $18m (@3.0c) under the ticker ZLD Commenced a
Slide 4: Market Differentiation, Key Products and Research Focus
Professor Guzmán is the Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University. His PhD and postdoctoral research focused on the Market Differentiation study of the regulation of liver and brain lipid metabolism. During the last twenty years he has been mostly involv
Slide 5: Pre-Clinical Research: Breast Cancer Studies
of action studies, testing other formulations of Zelda cannabinoids and also testing against other cancer cell Positive results of initial proof lines including HER2+ cells resistant to HER2-targetted of concept study into the treatments and triple-negative breast cancer cells. anti-cancer effects o
Slide 6: Pre-Clinical Research: Brain Cancer and Pancreatic Cancer
PRE-CLINICAL RESEARCH: PRE-CLINICAL RESEARCH: BRAIN CANCER PANCREATIC CANCER Zelda Therapeutics Ltd is working with the highly regarded, Perth-based Telethon Kids Institute Zelda Therapeutics has entered into a research collaboration agreement with Curtin University (www.telethonkids.org.au). This c
Slide 7: Clinical Trials for Sleep Disorders
Upon achieving positive results in the trial, Zelda will pursue the necessary approvals in key geographic markets to register the product and make it available for sale to consumers as an effective sleep aid. Trial sites identified in Substantial Discussions with Clinical multiple target anecdotal e
Slide 8: Best Practice = High Quality Medicines
Best Practice = High Quality Medicines Zelda has put in place a number of relationships providing a diversified, global supply chain to source the required cannabis medicine in a number of jurisdictions including Australia, North & South America and Europe. This is a critical aspect for any company
Slide 9: Q&A with Harry Karelis, Executive Chairman
Key Strategic Market Drivers Q&A Since listing on the ASX late 2016, significant investor interest and demand saw the share price increase by nearly 70% over the first four weeks as a public company. with Harry Karelis, This strong shareholder interest is a reflection of the growing global demand ma
Zelda Therapeutics — Investor Presentation (February 2017) on 6ix